Glen Eagle Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $428K | Sell |
854
-2
| -0.2% | -$960 | 0.05% | 202 |
|
|
2026
Q1 | $421K | Hold |
856
| – | – | 0.06% | 186 |
|
|
2025
Q4 | $496K | Sell |
856
-6
| -0.7% | -$3.39K | 0.07% | 172 |
|
|
2025
Q3 | $418K | Buy |
862
+6
| +0.7% | +$2.79K | 0.06% | 194 |
|
|
2025
Q2 | $347K | Hold |
856
| – | – | 0.05% | 196 |
|
|
2025
Q1 | $426K | Sell |
856
-10
| -1% | -$5.42K | 0.07% | 152 |
|
|
2024
Q4 | $451K | Sell |
866
-12
| -1% | -$6.6K | 0.07% | 150 |
|
|
2024
Q3 | $543K | Sell |
878
-7
| -0.8% | -$4.14K | 0.09% | 140 |
|
|
2024
Q2 | $489K | Sell |
885
-33
| -4% | -$18.9K | 0.09% | 139 |
|
|
2024
Q1 | $534K | Sell |
918
-65
| -7% | -$36.5K | 0.1% | 139 |
|
|
2023
Q4 | $522K | Sell |
983
-115
| -10% | -$55.7K | 0.11% | 137 |
|
|
2023
Q3 | $556K | Sell |
1,098
-66
| -6% | -$35.2K | 0.13% | 121 |
|
|
2023
Q2 | $607K | Sell |
1,164
-3
| -0.3% | -$1.62K | 0.14% | 123 |
|
|
2023
Q1 | $673K | Buy |
1,167
+5
| +0.4% | +$2.82K | 0.17% | 110 |
|
|
2022
Q4 | $640K | Buy |
1,162
+34
| +3% | +$18K | 0.17% | 108 |
|
|
2022
Q3 | $572K | Sell |
1,128
-5
| -0.4% | -$2.8K | 0.17% | 113 |
|
|
2022
Q2 | $616K | Sell |
1,133
-5
| -0.4% | -$2.75K | 0.17% | 112 |
|
|
2022
Q1 | $672K | Sell |
1,138
-45
| -4% | -$25.9K | 0.18% | 119 |
|
|
2021
Q4 | $789K | Hold |
1,183
| – | – | 0.21% | 108 |
|
|
2021
Q3 | $676K | Sell |
1,183
-15
| -1% | -$8.23K | 0.2% | 115 |
|
|
2021
Q2 | $604K | Sell |
1,198
-34
| -3% | -$16K | 0.19% | 115 |
|
|
2021
Q1 | $562K | Sell |
1,232
-25
| -2% | -$11.9K | 0.2% | 110 |
|
|
2020
Q4 | $585K | Sell |
1,257
-16
| -1% | -$7.5K | 0.23% | 92 |
|
|
2020
Q3 | $562K | Sell |
1,273
-29
| -2% | -$12K | 0.25% | 86 |
|
|
2020
Q2 | $472K | Buy |
1,302
+10
| +0.8% | +$3.35K | 0.24% | 90 |
|
|
2020
Q1 | $366K | Hold |
1,292
| – | – | 0.26% | 93 |
|
|
2019
Q4 | $420K | Hold |
1,292
| – | – | 0.22% | 96 |
|
|
2019
Q3 | $376K | Hold |
1,292
| – | – | 0.25% | 90 |
|
|
2019
Q2 | $379K | Hold |
1,292
| – | – | 0.26% | 89 |
|
|
2019
Q1 | $354K | Sell |
1,292
-20
| -2% | -$4.98K | 0.26% | 88 |
|
|
2018
Q4 | $294K | Hold |
1,312
| – | – | 0.25% | 89 |
|
|
2018
Q3 | $320K | Buy |
1,312
+20
| +2% | +$4.6K | 0.23% | 96 |
|
|
2018
Q2 | $268K | Hold |
1,292
| – | – | 0.21% | 106 |
|
|
2018
Q1 | $267K | Hold |
1,292
| – | – | 0.22% | 104 |
|
|
2017
Q4 | $245K | Hold |
1,292
| – | – | 0.21% | 114 |
|
|
2017
Q3 | $244K | Sell |
1,292
-1,290
| -50% | -$234K | 0.23% | 108 |
|
|
2017
Q2 | $450K | Hold |
2,582
| – | – | 0.36% | 73 |
|
|
2017
Q1 | $397K | Hold |
2,582
| – | – | 0.34% | 78 |
|
|
2016
Q4 | $364K | Buy |
+2,582
| New | +$381K | 0.33% | 83 |
|
Other funds holding TMO
Glen Eagle Advisors's TMO Position: Q2 2026 in Review
Glen Eagle Advisors reduced its Thermo Fisher Scientific (TMO) stake by 0.23% in Q2 2026, selling an estimated $960 and leaving 854 shares worth $428K. The position accounts for 0.05% of the portfolio, ranked #202.
Glen Eagle Advisors first reported a position in TMO in Q4 2016 and has held it in 39 quarters since. The position peaked at $789K in Q4 2021. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Glen Eagle Advisors held 854 shares of Thermo Fisher Scientific worth $428K as of Q2 2026.
- Glen Eagle Advisors sold 2 Thermo Fisher Scientific shares in Q2 2026, an estimated $960.
- Thermo Fisher Scientific made up 0.05% of Glen Eagle Advisors's portfolio in Q2 2026, its #202 holding.
- Glen Eagle Advisors first reported a position in Thermo Fisher Scientific in Q4 2016 and has held it in 39 quarters since.
- Glen Eagle Advisors's Thermo Fisher Scientific position peaked at $789K in Q4 2021.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.